SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is trending as its high-performance, compliance-first Layer 1 network, validated at over 11 million transactions per second, integrates a live fiat anchor with Bridge, a Stripe company. This partnership enables seamless, regulated movements of traditional currencies and stablecoins, positioning KTA as crucial financial plumbing for institutional adoption in global payments. The community is actively discussing KTA's significant potential and perceived undervaluation, viewing it as an asymmetric opportunity in the evolving digital finance landscape.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending after receiving FDA approval for YARTEMLEA, the first and only therapy for transplant-associated thrombotic microangiopathy in adults and children, with commercial launch set for January. The community is buzzing with optimism, anticipating a massive short squeeze and significant undervaluation given the drug's market potential and the company's strategic partnership with Novo Nordisk. Discussion centers on the long-term holding prospects and potential for a buyout, despite some debate on near-term volatility.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is a major topic after its drug Aqvesme (mitapivat) secured FDA approval as the only therapy for alpha- and beta-thalassemia, tapping into a significant patient population. While this milestone is driving considerable optimism and discussions of upward potential within the community, some investors are weighing its label, which includes a Risk Evaluation and Mitigation Strategy (REMS), against the stock's recent price movements. This approval marks a key moment, particularly after earlier mixed results from a different clinical program.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending due to positive news on significant regulatory relief, including the lifting of a key consent order, alongside a strong earnings report that reinforced confidence in its ongoing transformation strategy. The community is actively debating if the stock's remarkable appreciation, which has seen it reach multi-year highs, is sustainable amidst discussions of overbought technical levels, despite a broader optimistic outlook for the financial sector.

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Biohaven Ltd

Biohaven Pharmaceutical Holding Company Ltd

Biohaven is trending as its depression drug candidate failed to meet the primary endpoint in a Phase 2 trial, prompting the company to shift its focus away from psychiatric indications. The community is discussing this latest setback, with many investors now pinning their hopes on the accelerated immunology, obesity, and epilepsy programs, particularly the highly anticipated epilepsy trial, as crucial future catalysts for a potential turnaround.

Sprott Physical Platinum and Palladium Trust - Unit

Sprott Physical Platinum & Palladium

Sprott Physical Platinum & Palladium is gaining significant attention following robust price appreciation, fueled by critical industrial demand for uses like catalytic converters and electronics. Community discussion highlights the metals' under-owned status and supply risks from key producing nations, prompting expectations of a continued breakout as investors seek diversification. Many see potential for Platinum to reclaim its historical premium over gold.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is currently a major talking point following the announcement that Sanofi has agreed to acquire the company for $15.50 per share, a deal valued at approximately $2.2 billion to expand Sanofi's adult immunization offerings. While many investors are celebrating the long-awaited exit and the premium offered, a significant portion of the community expresses strong disappointment, arguing the acquisition price notably undervalues Dynavax's Hepatitis B vaccine and promising shingles pipeline.

iRhythm Technologies, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. It also provides solutions that detect, predict, and prevent disease. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.

iRhythm Technologies Inc

iRhythm Technologies is generating significant buzz following a flurry of bullish analyst upgrades and compelling AMALFI study data that validates the superior performance of its Zio service for AFib detection. The community is actively discussing this strong fundamental and institutional interest, which appears to be outweighing recent bearish sentiment, highlighting the company's innovation in the digital cardiac monitoring space. This momentum is further supported by recent positive earnings and strategic operational advancements, positioning IRTC as a key player in healthcare technology.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA Group is experiencing strong upward momentum, driven by recent positive analyst coverage and a community belief that the stock is oversold and poised for a significant rebound. Investors are actively discussing the company's disciplined expansion, profitability, and strong unit economics, positioning it as a compelling long-term growth play within the fast-casual restaurant sector.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is seeing a surge in attention following preliminary analysis from its FLAMINGO-01 trial, which revealed an estimated 80% reduction in breast cancer recurrence. The community is highly optimistic, citing consistent insider buying by the CEO and an exceptionally high cost-to-borrow rate that has shorts in a precarious position, leading to widespread speculation of an imminent short squeeze. Investors are positioning for potential multi-billion dollar partnerships or a buyout, believing the stock is significantly undervalued given its promising clinical progress in cancer immunotherapy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TPI Composites (TPIC) stock fell 38% in premarket trading on Tuesday after the wind Turbine blade maker filed for bankruptcy to restructure its debt.The company stated that one of its lenders, Oaktree Capital Management, has agreed to provide support with $27.5 million in new capital, as well as $55 million from its existing loan agreement, to support its day-to-day operations. Oaktree has also allowed TPI to use cash collateral.“Despite recent progress, industry-wide pressures have created financial challenges that must be addressed. We explored a variety of alternatives to address the challenges facing the Company and believe that a Chapter 11 process is necessary to position the Company for success,” said Bill Siwek, Chief Executive Officer of TPI.Retail sentiment on Stocktwits was in the ‘extremely bullish’ territory, while retail chatter was ‘extremely high.’<figure class="image"><img style="aspect-ratio:808/96;" src="https://news.stocktwits-cdn.com/TPIC_Aug_12_JPG_93ed7bdc19.webp" alt="TPIC-Aug 12.JPG" width="808" height="96"><figcaption>TPIC’s Sentiment Meter and Message Volume as of 05:14 a.m. ET on Aug. 12, 2025 | Source: Stocktwits</figcaption></figure>The company listed estimated assets between $500 million and $1 billion, with liabilities between $1 billion and $10 billion, Bloomberg News reported, citing a bankruptcy court filing dated Monday.The wind equipment maker’s bankruptcy filing hints toward a continued downward spiral for the once-booming industry in the U.S. Since taking office for the second time, U.S. President Donald Trump has severely criticized large wind projects, and his Republican allies in Congress have moved to slash incentives for new projects."Will be interesting to see how this goes short term… sounds like they were making progress but due to market conditions they are doing this voluntarily to come back stronger?" one user said.<stembedurl>https://stocktwits.com/notsurewhat/message/624704980</stembedurl>The company reported a net loss of $48.3 million for the first quarter, along with sales of $336.4 million. It has manufacturing facilities in the U.S., Spain, Turkey, and India, and customers include Vestas and GE.TPI stock has plunged nearly 85% this year.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-coal-producer-hallador-energy-s-stock-is-soaring-premarket-today/chrDCOARd7j">Why Coal Producer Hallador Energy’s Stock Is Soaring Premarket Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wind farm and solar panels seen from the air during a beautiful morning with mist and sun. Muntendam, Groningen, the Netherlands, September 2023.

TPI Composites Stock Sinks Premarket: What’s Behind The Slide?

The wind turbine blade maker has filed for bankruptcy, listing estimated assets of between $500 million and $1 billion, with liabilities ranging from $1 billion to $10 billion.

Equity

TPI Composites (TPIC) Reports Q2 Loss, Lags Revenue Estimates

TPI Composites (TPIC) delivered earnings and revenue surprises of -161.11% and -25.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

LegalZoom (LZ) Q2 Earnings Meet Estimates

LegalZoom (LZ) delivered earnings and revenue surprises of 0.00% and +5.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

TPI Composites (TPIC) Reports Q1 Loss, Tops Revenue Estimates

TPI Composites, Inc. is a holding company, which engages in the manufacturing of composite wind blades for the wind energy market. It operates through the following geographical segments: United States (US), Mexico, Europe, the Middle East and Africa (EMEA), and India. The US segment manufactures precision molding and assembly systems used for automotive business at Warren, Rhode Island facility. The Mexico segment includes the manufacturing of wind blades at three facilities in Juárez, Mexico, and two facilities in Matamoros, Mexico. The EMEA segment refers to the manufacturing of wind blades at two facilities in Izmir, Türkiye, and wind blade inspection and repair services in Türkiye. The India segment manufactures wind blades at manufacturing facility in Chennai, India. The company was founded by Everett Pearson and Neil Tillotson in 1968 and is headquartered in Scottsdale, AZ.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.08	--	--	N/A
Q3 '25	-$0.12	--	--	N/A
Q2 '25	-$0.60	-$1.40	-133.33%	MISSED
Q1 '25	-$0.51	-$1.01	-97.62%	MISSED
Q4 '24	-$0.37	-$1.01	-171.50%	MISSED

TPIC
TPI Composites Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest TPIC News

TPICTPI Composites Inc